Overexpression of sFasL using the AAV2-mediated gene therapy approach prevented axon degeneration and death of RGCs in both inducible and chronic mouse models of glaucoma, and this neuroprotection correlated with an inhibition of Müller glia activation and induction of inflammatory mediators [31]. This evidence concerns the gene FASLG and glaucoma.